9 results
8-K
EX-99.1
ALIM
Alimera Sciences Inc.
7 Mar 24
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
8:32am
.
Completed recruitment in the landmark NEW DAY Study for ILUVIEN, which is a multicenter, masked, randomized, controlled trial designed to generate … recruitment in the Synchronicity Study for YUTIQ, which is a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ
8-K
EX-2.1
ALIM
Alimera Sciences Inc.
18 May 23
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023
4:55pm
., investigator brochures, informed consent forms, data safety monitoring board related documents, patient recruitment related materials, biocompatibility
8-K
ALIM
Alimera Sciences Inc.
4 Dec 12
Alimera Sciences Signs Agreement with Quintiles for European
12:00am
the Agreement with respect to the provision of services related to the recruitment, employment, deployment and administration of a commercialization team … and other benefits, equipment, recruitment, and management and administration) and (ii) a mutually agreed upon margin on the total of such costs. Alimera
8-K
EX-99.1
ALIM
Alimera Sciences Inc.
4 Dec 12
Alimera Sciences Signs Agreement with Quintiles for European
12:00am
services related to recruitment, employment, deployment and administration of the ILUVIEN commercialization team in Germany through December 31, 2015
10-K
2010 FY
EX-10.29
ALIM
Alimera Sciences Inc.
25 Mar 11
Annual report
12:00am
to Iluvien® upon the mutual written agreement of the Company and OnCall. OnCall services will include sales force recruitment, employment, and administration … The Following Services Under This Agreement, Which Services Are Included Within The Fees Listed Below:
Field Sales Force Recruitment, Employment
8-K
t12xexalk pke
6 Oct 10
Entry into a Material Definitive Agreement
12:00am
S-1/A
EX-10.12
6b43kmqg
19 Aug 08
IPO registration (amended)
12:00am
- Prev
- 1
- Next